Photo from wikipedia
Polyomavirus‐associated nephropathy (PVAN) remains a relevant complication following kidney transplantation with allograft loss rates of up to 50%. Reduction in overall immunosuppression is a cornerstone of therapy, whereas no specific… Click to show full abstract
Polyomavirus‐associated nephropathy (PVAN) remains a relevant complication following kidney transplantation with allograft loss rates of up to 50%. Reduction in overall immunosuppression is a cornerstone of therapy, whereas no specific antiviral regimen has shown conclusive benefit to date. The present case series demonstrates the efficacy of a dual therapeutic approach with low‐dose cidofovir and conversion to mTOR‐based immunosuppression in PVAN.
Keywords:
associated nephropathy;
low dose;
dose cidofovir;
polyomavirus associated;
cidofovir conversion;
immunosuppression
Journal Title: Transplant Infectious Disease
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Transplant Infectious Disease
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!